top of page
Colorful Abstract Shapes

Novo Secures EU Approval for New Haemophilia A Treatment

Writer: G-Med Team
G-Med Team
3 days ago
2 min read

Novo has received European Commission approval for Frehemgo (denecimig), a new treatment designed to prevent or reduce bleeding episodes in patients with haemophilia A. Announced on November 13, 2026, the approval marks an important development in the management of this rare genetic bleeding disorder, offering an additional treatment option for adults and children, including patients with or without factor VIII inhibitors.


Haemophilia A is a hereditary bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII, a protein essential for normal blood coagulation. Patients may experience spontaneous bleeding, prolonged bleeding following injuries, and recurrent joint bleeds that can lead to long-term complications, including joint damage and reduced mobility. Effective preventive treatment is therefore essential to improving long-term outcomes and quality of life.

Modern Novo Nordisk office building with a large blue logo sign in front

Frehemgo is a next-generation antibody designed to mimic the activity of activated factor VIII, supporting the blood-clotting process without directly replacing the missing protein. Administered through subcutaneous injection, the treatment offers three dosing schedules: once monthly, every two weeks, or weekly. This flexibility may allow physicians to tailor preventive treatment according to individual patient needs, clinical circumstances, and preferences.


The European Commission's decision follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September 2026. Approval was supported by Novo's clinical development programme, which evaluated the treatment's ability to prevent bleeding episodes. According to the company, clinical findings demonstrated significant reductions in annualised bleeding rates compared with patients' previous prophylactic and on-demand treatments.


These findings suggest that Frehemgo could provide an additional preventive option for patients with haemophilia A, particularly those who have developed inhibitors that complicate traditional factor VIII replacement therapy.


Novo plans to introduce Frehemgo in its first European markets over the coming year, expanding access to innovative haemophilia care. Meanwhile, regulatory review in the United States remains ongoing, following an extension of the FDA's review in October 2026 related to manufacturing facility remediation.


For healthcare professionals, the approval represents another step towards more flexible and personalised haemophilia management. Treatment selection will continue to depend on individual bleeding risk, previous treatment response, safety considerations, and patient preferences.


As Frehemgo becomes available across Europe, real-world clinical experience will be important in establishing its long-term effectiveness, safety, and role in routine practice. The approval highlights the continued evolution of haemophilia treatment, with innovation increasingly focused on effective bleeding prevention, reduced treatment burden, and improved patient outcomes.


G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: 

 
 
bottom of page